Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Domino's new chicken brand is 'low risk', says Shore Capital

(Sharecast News) - Shore Capital has praised the launch of Domino's Pizza Group's new chicken-focused sub-brand, CHICK 'N' DIP, but has retained its 'hold' recommendation due to macro concerns. DPG, the UK master franchise of the American fast-food chain, said on 8 September that it was trialling CHICK 'N' DIP in nearly 190 stores across the northwest of England and Northern Ireland.

The trial, which will run in 187 stores before being scaling nationally, marks "a bold new chapter for Domino's", according to Andrew Rennie, chief executive.

Shore Capital called it a "low-risk strategy", given Domino's is using its existing fulfilment and distribution facilities to test expansion, but noted that the chicken market in the UK is "competitive", with growing investment from leading players.

"There is a growing market to potentially grow within; however, we feel that most of the current chicken QSR offerings are fairly comparable and competitive. Ultimately, it is likely to come down to customer brand loyalty, in our view and habits," the broker said.

"We believe there is a lot to like about Domino's, including its strong brand awareness, well-funded balance sheet, and development into loyalty, which could support customer frequency. However, whilst we appreciate these qualities and note the stock remains optically cheap at c.9x EBITDA, with an 8% FCFY, our 'hold' stance reflects our concern about the current consumer backdrop of low confidence and slowing discretionary income."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.